Skip to main content
Log in

Clinical effects and plasma levels of Δ9-Tetrahydrocannabinol (Δ9-THC) in heavy and light users of cannabis

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript


Δ9-Tetrahydrocannabinol (Δ9-THC) was administered in a crossover design by smoking and IV injection to groups of heavy and light users of marihuana. Plasma concentrations of Δ9-THC were similar for the groups after IV injection of 5.0 mg Δ9-THC, but the AUC0–240 min showed a trend towards lower values for the heavy user group. To achieve a maximum desired “high”, both groups smoked similar amounts (about 13 mg) of Δ9-THC. Heavy users tended to have higher plasma levels than light users. The systemic availability of smoked Δ9-THC was significantly higher for the heavy users (heavy users 23±16% vs 10±7% for light users). These results also indicate that heavy cannabis users smoke more efficiently than casual smokers.

Both light and heavy users showed more clinical effect following IV administration than after smoking. The response of the heavy users, both with respect to effect on heart and “high”, was quite comparable to that of light users.

The present study does not suggest that tolerance readily develops in heavy users.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others


  • Benowitz NL, Jones RT (1977) Effects of Δ9-tetrahydrocannabinol on drug distribution and metabolism. Clin Pharmacol Ther 22:259–268

    Google Scholar 

  • Hollister LE (1973) Cannabidiol and cannabinol in man. Experientia 29:825–826

    Google Scholar 

  • Hollister LE (1979) Cannabis and the development of tolerance. In: Nahas G, Paton WDM (eds) Marihuana: Biological effects. Pergamon Press, London, pp 585–589

    Google Scholar 

  • Hollister LE, Kanter SL, Moore F, Green DE (1972) Marihuana metabolites in urine of man. Clin Pharmacol Ther 13:849–855

    Google Scholar 

  • Lemberger L, Rubin A (1976) Physiologic disposition of drugs of abuse. Spectrum Publications, New York, pp 269–310

    Google Scholar 

  • Lemberger L, Silberstein SD, Axelrod J, Kopin IJ (1970) Marihuana: Studies on the disposition and metabolism of Δ9-tetrahydrocannabinol in man. Science 170:1320–1322

    Google Scholar 

  • Ohlsson A, Lindgren JE, Wahlén A, Agurell S, Hollister LE, Gillespie H (1980) Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28:409–416

    Google Scholar 

  • Perez-Reyes M, Timmons MC, Wall ME (1974) Long-term use of marihuana and the development of tolerance or sensitivity to Δ9-tetrahydrocannabinol. Arch Gen Psychiatry 31:89–91

    Google Scholar 

  • Willette RE, ed. (1976) Cannabinoid assays in humans. NIDA Research Monograph 7. National Institute on Drug Abuse, Rockville

    Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and permissions

About this article

Cite this article

Lindgren, JE., Ohlsson, A., Agurell, S. et al. Clinical effects and plasma levels of Δ9-Tetrahydrocannabinol (Δ9-THC) in heavy and light users of cannabis. Psychopharmacology 74, 208–212 (1981).

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI:

Key words